Investors & News | Ascendis Pharma
WEBSep 3, 2024 · Investors & News. Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
News Releases - Ascendis Pharma
WEBNov 18, 2021 · Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism.
After 2 delays over 15 months, FDA approves Ascendis' Yorvipath
WEBAug 12, 2024 · After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the US.
News Release - Ascendis Pharma
WEBMay 1, 2023 · U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism. May 1, 2023 at 7:00 AM EDT. PDF Version. FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product.
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
WEB4 days ago · Ascendis Pharma. COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of ...
Ascendis Pharma Presents New Data and Updated Results from …
WEBJun 3, 2024 · Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Ascendis Pharma Receives Buy Rating Amid Positive Phase 3 …
WEBSep 16, 2024 · Analyst Paul Choi of Goldman Sachs maintained a Buy rating on Ascendis Pharma (ASND – Research Report), boosting the price target to $200.00. Paul Choi has given his Buy rating due to a ...
Ascendis Pharma A/S (ASND) Latest Stock News & Headlines
WEBGet the latest Ascendis Pharma A/S (ASND) stock news and headlines to help you in your trading and investing decisions.
Buy Rating on Ascendis Pharma as TransCon CNP ... - Markets …
WEB6 days ago · In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of $207.00. David Lebovitz has given his Buy ...
Ascendis trial data piles pressure on BioMarin | BioPharma Dive
WEB5 days ago · On Monday, Ascendis Pharma released summary results from a clinical trial testing a treatment that, like BioMarin’s drug, is designed to treat children with achondroplasia, ... The news sent Ascendis shares up by 17% and pushed BioMarin’s down by 18% Monday, reflecting Wall Street’s reset expectations for how much of the achondroplasia ...